Production (Stage)
Haemonetics Corporation
HAE
$67.53
$1.472.23%
NYSE
| 03/29/2025 | 12/28/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 184.68% | 20.02% | 35.82% | -6.50% | -30.68% |
| Total Depreciation and Amortization | 12.97% | 23.35% | 26.19% | 27.28% | 24.00% |
| Total Amortization of Deferred Charges | -22.09% | -- | -- | -- | -8.24% |
| Total Other Non-Cash Items | -405.23% | -33.76% | -20.31% | -280.09% | -80.24% |
| Change in Net Operating Assets | 225.50% | 54.47% | -194.80% | -59.72% | 59.68% |
| Cash from Operations | 81.89% | 8,204.81% | -50.75% | -243.67% | -19.51% |
| Capital Expenditure | -134.00% | -162.29% | 51.42% | -2.11% | 43.91% |
| Sale of Property, Plant, and Equipment | 344.83% | -25.74% | -63.58% | 4,965.17% | 109.05% |
| Cash Acquisitions | -- | 100.00% | -- | -- | -- |
| Divestitures | 2,786.07% | -- | -- | -- | -- |
| Other Investing Activities | -43.18% | 44.06% | -882.50% | 90.98% | -- |
| Cash from Investing | 238.17% | 93.54% | 7.03% | -812.11% | 27.49% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | 97.54% | 55.37% | 2,620.00% | -33,486.46% | -3,528.57% |
| Issuance of Common Stock | 32.08% | 21.32% | -63.73% | 25.84% | -33.33% |
| Repurchase of Common Stock | -- | -944.19% | -1,621.59% | -557.45% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 75.00% | -375.93% | -1,764,120.00% | -2,587.95% | -800.00% |
| Cash from Financing | -138.50% | -98.74% | -943.00% | 55,901.34% | -3,861.45% |
| Foreign Exchange rate Adjustments | 202.55% | -305.63% | 374.46% | 26.80% | -684.63% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 7.21% | 113.73% | -169.15% | 13,118.60% | -125.10% |